Rexahn begins Phase IIa trial of renal carcinoma drug Archexin

US-based clinical stage biopharmaceutical firm Rexahn Pharmaceuticals has started a multi-centre Phase IIa clinical proof-of-concept trial to evaluate the safety and efficacy of Archexin in patients with metastatic renal cell carcinoma (RCC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news